Cite
Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential significant biomarkers.
MLA
Park, Ji, et al. “Phase II Trial of Neoadjuvant Letrozole and Lapatinib in Asian Postmenopausal Women with Estrogen Receptor (ER) and Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [Neo-ALL-IN]: Highlighting the TILs, ER Expressional Change after Neoadjuvant Treatment, and FES-PET as Potential Significant Biomarkers.” Cancer Chemotherapy & Pharmacology, vol. 78, no. 4, Oct. 2016, pp. 685–95. EBSCOhost, https://doi.org/10.1007/s00280-016-3107-6.
APA
Park, J., Kang, M., Ahn, J.-H., Kim, J., Jung, K., Gong, G., Lee, H., Son, B.-H., Ahn, S.-H., Kim, H.-H., Shin, H., Moon, D.-H., Kim, S.-B., Park, J. H., Kang, M. J., Kim, J. E., Jung, K. H., Lee, H. J., & Shin, H. J. (2016). Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential significant biomarkers. Cancer Chemotherapy & Pharmacology, 78(4), 685–695. https://doi.org/10.1007/s00280-016-3107-6
Chicago
Park, Ji, Myung Kang, Jin-Hee Ahn, Jeong Kim, Kyung Jung, Gyungyub Gong, Hee Lee, et al. 2016. “Phase II Trial of Neoadjuvant Letrozole and Lapatinib in Asian Postmenopausal Women with Estrogen Receptor (ER) and Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [Neo-ALL-IN]: Highlighting the TILs, ER Expressional Change after Neoadjuvant Treatment, and FES-PET as Potential Significant Biomarkers.” Cancer Chemotherapy & Pharmacology 78 (4): 685–95. doi:10.1007/s00280-016-3107-6.